Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.
Beth Boulden WarrenLinda JacobsonChristine L KemptonGeorge R BuchananMichael RechtDeborah BrownCindy LeissingerAmy D ShapiroThomas C AbshireMarilyn J Manco-Johnsonnull nullPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)
In the JOS, the effect of prescribed prophylactic FVIII infusions on joint outcome overshadowed the contribution of treatment adherence, FVIII half-life, global assays of coagulation and constitutional coagulation proteins. (ClinicalTrials.gov number, NCT00207597).